{
    "data": [
        {
            "id": "69a1a71624c37e0001bbf8d0",
            "title": "Here&#39;s How Much $100 Invested In Axon Enterprise 5 Years Ago Would Be Worth Today",
            "description": "<div><div class=\"sc-gfrmXj kPLDLR\"><!--$--><p class=\"block core-block\">Axon Enterprise (NASDAQ:<a class=\"ticker\" href=\"https://www.benzinga.com/quote/AXON\" target=\"_blank\">AXON</a>) has outperformed the market over the past 5 years by 14.79% on an annualized basis producing an average annual return of 27.06%. Currently, Axon Enterprise has a market capitalization of $43.31 billion. </p><!--/$--><!--$--><p class=\"block core-block\"><strong>Buying $100 In AXON:</strong> If an investor had bought $100 of AXON stock 5 years ago, it would be worth <strong>$324.31</strong> today based on a price of $545.17 for AXON at the time of writing.</p><!--/$--><!--$--><h3 class=\"block core-block\">Axon Enterprise's Performance Over Last 5 Years</h3><!--/$--><!--$?--><template id=\"B:1\"></template><div></div><!--/$--><!--$--><p class=\"block core-block\">Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.</p><!--/$--><!--$--><p class=\"block core-block\"><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p><!--/$--><!--$--><div class=\"sc-jHrKIi gTZsSs\"></div><!--/$--></div></div>",
            "image": "",
            "link": "https://www.benzinga.com/insights/news/26/02/50927220/heres-how-much-100-invested-in-axon-enterprise-5-years-ago-would-be-worth-today",
            "pub_date": "2026-02-27 22:15:54",
            "source": "benzinga",
            "kind": 1,
            "language": "en"
        },
        {
            "id": "69a1a77d24c37e0001bbf922",
            "title": "Generic Drugs Focused Amneal Pharmaceuticals Revenue Crosses $800 Million",
            "description": "<div><div class=\"sc-gfrmXj kPLDLR\"><!--$--><p class=\"block core-block\"><strong>Amneal Pharmaceuticals Inc. </strong><a class=\"ticker-link\" data-exchange=\"NASDAQ\" data-ticker=\"AMRX\" href=\"https://www.benzinga.com/quote/AMRX\" rel=\"noopener\" target=\"_blank\">(NASDAQ:</a><a class=\"ticker\" href=\"https://www.benzinga.com/quote/AMRX\" target=\"_blank\">AMRX</a>)<!-- --> released its <a href=\"https://www.benzinga.com/pressreleases/26/02/g50921160/amneal-reports-fourth-quarter-and-full-year-2025-financial-results\" rel=\"noreferrer noopener\" target=\"_blank\">recent financial results</a> announcement on Friday.</p><!--/$--><!--$--><p class=\"block core-block\">Amneal Pharmaceuticals announced its fourth-quarter revenue of $814.32 million, an 11% increase year over year, beating the <a href=\"https://www.benzinga.com/calendars/earnings\" rel=\"noreferrer noopener\" target=\"_blank\">consensus of $807.89 million</a>.</p><!--/$--><!--$--><div class=\"min-w-[300px] w-[300px] min-h-[250px] raptive-ad-placement mx-auto overflow-hidden min-w-[300px]\"></div><!--/$--><!--$--><p class=\"block core-block\">The generic drug maker reported adjusted earnings of 21 cents, beating the Wall Street estimate of 18 cents.</p><!--/$--><!--$--><p class=\"block core-block\">In the fourth quarter, adjusted EBITDA reached $175 million, reflecting a 13% increase year-over-year.</p><!--/$--><!--$--><p class=\"block core-block\">The company highlighted the strong uptake of its specialty products, particularly CREXONT, while also noting a robust cadence of new product approvals in its Affordable Medicines segment.</p><!--/$--><!--$--><div class=\"sc-jHrKIi gTZsSs\"></div><!--/$--><!--$--><h2 class=\"wp-block-heading\">Guidance</h2><!--/$--><!--$--><p class=\"block core-block\">Amneal Pharmaceuticals expects fiscal 2026 adjusted earnings between 93 cents and $1.03, compared to the <a href=\"https://www.benzinga.com/calendars/guidance\" rel=\"noreferrer noopener\" target=\"_blank\">consensus of 94 cents</a>.</p><!--/$--><!--$--><p class=\"block core-block\">The company expects 2026 sales of $3.05-$3.15 billion versus the consensus of $3.21 billion.</p><!--/$--><!--$--><p class=\"block core-block\">The company expects adjusted EBITDA of $720 million-$760 million, with operating cash flow of $325 million-$375 million.</p><!--/$--><!--$--><div class=\"min-w-[300px] w-[300px] min-h-[250px] raptive-ad-placement mx-auto overflow-hidden min-w-[300px]\"></div><!--/$--><!--$--><h2 class=\"wp-block-heading\">Technical Analysis</h2><!--/$--><!--$--><p class=\"block core-block\">The stock is currently trading 5.2% below its 20-day simple moving average (SMA) and 6.8% below its 100-day SMA, indicating some short-term weakness. Over the past 12 months, shares have increased by 16%, and they are currently positioned closer to their 52-week highs than lows, suggesting a generally positive trend.</p><!--/$--><!--$--><p class=\"block core-block\">The RSI is at 50.00, which is considered neutral territory, indicating that the stock is neither overbought nor oversold. Meanwhile, MACD is at 0.10, below its signal line at 0.15, suggesting bearish pressure on the stock.</p><!--/$--><!--$--><div class=\"min-w-[300px] w-[300px] min-h-[250px] raptive-ad-placement mx-auto overflow-hidden min-w-[300px]\"></div><!--/$--><!--$--><p class=\"block core-block\">The combination of neutral RSI and bearish MACD suggests mixed momentum, indicating that traders should watch for potential shifts in market sentiment.</p><!--/$--><!--$--><ul class=\"wp-block-list\">\n<li><strong>Key Resistance</strong>: $15.00</li>\n<li><strong>Key Support</strong>: $13.00</li>\n</ul><!--/$--><!--$--><p class=\"block core-block\"><strong>Analyst Consensus &amp; Recent Actions:</strong> The stock carries a Buy Rating with an <a href=\"https://www.benzinga.com/quote/NASDAQ:AMRX/analyst-ratings\" rel=\"noreferrer noopener\" target=\"_blank\">average price target</a> of $11.83. Recent analyst moves include:</p><!--/$--><!--$--><ul class=\"wp-block-list\">\n<li><strong>Barclays</strong>: Initiated with Overweight (Target $15.00) (Dec. 9, 2025)</li>\n</ul><!--/$--><!--$--><div class=\"nativo-placement-in-content-ap\"></div><!--/$--><!--$--><p class=\"block core-block\"><strong>AMRX Price Action:</strong> Amneal Pharmaceuticals shares were up 0.76% at $14.60 during premarket trading on Friday, according to <a href=\"https://pro.benzinga.com/dashboard\" rel=\"noreferrer noopener\" target=\"_blank\">Benzinga Pro data</a>.</p><!--/$--><!--$--><p class=\"block core-block\"><em>Photo by Martin Gregor via Shutterstock</em></p><!--/$--><!--$--><div class=\"bz-optimizely-campaign bz-optimizely-campaign-bottom-50927300\" data-nosnippet=\"true\"></div><!--/$--></div></div>",
            "image": "https://www.benzinga.com/files/images/story/2026/02/27/Pill-Bottle-And-Pills-On-Blue-Background.jpeg",
            "link": "https://www.benzinga.com/markets/earnings/26/02/50927300/generic-drugs-focused-amneal-pharmaceuticals-revenue-crosses-800-million",
            "pub_date": "2026-02-27 22:17:36",
            "source": "benzinga",
            "kind": 1,
            "language": "en"
        },
        {
            "id": "69a1a6d624c37e0001bbf8b2",
            "title": "Why Is Bakkt Stock Falling Friday?",
            "description": "<div><div class=\"sc-gfrmXj kPLDLR\"><!--$--><p class=\"block core-block\"><strong>Bakkt, Inc.</strong> <a href=\"https://www.benzinga.com/quote/BKKT\" rel=\"noreferrer noopener\" target=\"_blank\"></a><a class=\"ticker-link\" data-exchange=\"NYSE\" data-ticker=\"BKKT\" href=\"https://www.benzinga.com/quote/BKKT\" rel=\"noopener\" target=\"_blank\">(NYSE:</a><a class=\"ticker\" href=\"https://www.benzinga.com/quote/BKKT\" target=\"_blank\">BKKT</a>)<!-- --> shares are down during Friday’s premarket session as <a href=\"https://www.benzinga.com/pressreleases/26/02/g50923894/bakkt-announces-pricing-of-48-125-million-registered-direct-offering\" rel=\"noreferrer noopener\" target=\"_blank\">the company announced</a> a registered direct offering. Bakkt specializes in institutional-grade solutions focused on security, scale, and regulatory compliance — and while the latest offering could fund these initiatives, bearish market sentiment remains a concern.</p><!--/$--><!--$--><h2 class=\"wp-block-heading\">Bakkt Announces $48.125M Direct Offering</h2><!--/$--><!--$--><div class=\"min-w-[300px] w-[300px] min-h-[250px] raptive-ad-placement mx-auto overflow-hidden min-w-[300px]\"></div><!--/$--><!--$--><p class=\"block core-block\">Bakkt announced the pricing of a registered direct offering of 3,024,799 shares of Class A common stock and pre-funded warrants to purchase up to 2,475,201 shares (totaling approximately 5.5 million shares) at $8.75 per share to a single institutional investor, with gross proceeds of $48.125 million</p><!--/$--><!--$--><p class=\"block core-block\">The offering is set to close around March 2, 2026, with proceeds earmarked for working capital, general corporate purposes, and strategic initiatives.</p><!--/$--><!--$--><p class=\"block core-block\">The dilutive nature of the share offering — common in such direct placements — is likely driving the premarket decline in the share price following the announcement. The offering is limited to jurisdictions where such transactions are legally permitted under applicable securities laws.</p><!--/$--><!--$--><div class=\"sc-jHrKIi gTZsSs\"></div><!--/$--><!--$--><h2 class=\"wp-block-heading\">Bakkt’s Stock Faces 10.34% Yearly Decline</h2><!--/$--><!--$--><p class=\"block core-block\">Over the past year, Bakkt’s stock has faced a downward trend, declining by 10.34%. Currently, the stock is trading significantly below its key moving averages, which signals bearish sentiment in the market. Specifically, it is 16.8% below the 20-day SMA and a stark 50.4% below the 100-day SMA. These indicators suggest the stock has struggled to regain bullish momentum over the medium- to long-term.</p><!--/$--><!--$--><h2 class=\"wp-block-heading\">Anticipated Bakkt Earnings Report: March 18, 2026</h2><!--/$--><!--$--><p class=\"block core-block\">Looking further out, the next major catalyst for the stock arrives with the March 18, 2026, earnings report. Here are the anticipated financial metrics and analyst perspectives:</p><!--/$--><!--$--><ul class=\"wp-block-list\">\n<li><strong>EPS Estimate</strong>: Loss of 47 cents (Up from a loss of $2.95 YoY)</li>\n<li><strong>Revenue Estimate</strong>: $279.87 million (Down from $1.80 billion YoY)</li>\n</ul><!--/$--><!--$--><div class=\"min-w-[300px] w-[300px] min-h-[250px] raptive-ad-placement mx-auto overflow-hidden min-w-[300px]\"></div><!--/$--><!--$--><p class=\"block core-block\"><strong>Analyst Consensus &amp; Recent Actions:</strong> The stock carries a Hold Rating with an <a href=\"https://www.benzinga.com/quote/BKKT/analyst-ratings\" rel=\"noreferrer noopener\" target=\"_blank\">average price target</a> of $52.85. Recent analyst moves include:</p><!--/$--><!--$--><ul class=\"wp-block-list\">\n<li><strong>Benchmark</strong>: Initiated with Buy (Target $13.00) (Sep. 8, 2025)</li>\n</ul><!--/$--><!--$--><h2 class=\"wp-block-heading\">Bakkt’s Benzinga Edge: A Cautious Outlook</h2><!--/$--><!--$--><p class=\"block core-block\">Below is the <a href=\"https://www.benzinga.com/screener\" rel=\"noreferrer noopener\" target=\"_blank\">Benzinga Edge scorecard</a> for Bakkt, highlighting its strengths and weaknesses compared to the broader market:</p><!--/$--><!--$--><ul class=\"wp-block-list\">\n<li><strong>Momentum</strong>: Neutral (Score: 40.76) — The company shows moderate market momentum.</li>\n</ul><!--/$--><!--$--><div class=\"min-w-[300px] w-[300px] min-h-[250px] raptive-ad-placement mx-auto overflow-hidden min-w-[300px]\"></div><!--/$--><!--$--><p class=\"block core-block\"><strong>The Verdict:</strong> Bakkt’s Benzinga Edge signal reflects a cautious outlook, with recent stock price action and internal challenges outweighing modest momentum resilience.</p><!--/$--><!--$--><p class=\"block core-block\"><strong>Short interest </strong>in Bakkt <a href=\"https://www.benzinga.com/quote/BKKT/short-interest\" rel=\"noreferrer noopener\" target=\"_blank\">rose</a> from 4.19M to 4.47M shares, representing 27.78% of publicly available shares. At an average daily volume of 1.18M shares, it would take approximately 3.78 days for short sellers to cover their positions.</p><!--/$--><!--$--><p class=\"block core-block\"><strong>BKKT Price Action:</strong> Bakkt shares were down 6.06% at $9.77 during premarket trading on Friday, <a href=\"https://www.benzinga.com/pro/\" rel=\"noreferrer noopener\" target=\"_blank\">according to Benzinga Pro data</a>.</p><!--/$--><!--$--><p class=\"block core-block\"><em>Photo by T. Schneider via Shutterstock</em></p><!--/$--><!--$--><div class=\"bz-optimizely-campaign bz-optimizely-campaign-bottom-50927192\" data-nosnippet=\"true\"></div><!--/$--></div></div>",
            "image": "https://www.benzinga.com/files/images/story/2026/02/27/Stuttgart--Germany---07-03-2024-Mobile-P.jpeg",
            "link": "https://www.benzinga.com/trading-ideas/movers/26/02/50927192/why-is-bakkt-stock-falling-friday",
            "pub_date": "2026-02-27 22:14:50",
            "source": "benzinga",
            "kind": 1,
            "language": "en"
        },
        {
            "id": "69a1a6df24c37e0001bbf8b3",
            "title": "Zscaler Analysts Slash Their Forecasts After Q2 Results",
            "description": "<div><div class=\"sc-gfrmXj kPLDLR\"><!--$--><p class=\"block core-block\"><strong>Zscaler Inc.</strong> <a class=\"ticker-link\" data-exchange=\"NASDAQ\" data-ticker=\"ZS\" href=\"https://www.benzinga.com/quote/ZS\" rel=\"noopener\" target=\"_blank\">(NASDAQ:</a><a class=\"ticker\" href=\"https://www.benzinga.com/quote/ZS\" target=\"_blank\">ZS</a>)<!-- --> on Thursday reported better-than-expected second-quarter financial results <a href=\"https://www.benzinga.com/quote/ZS/earnings\" target=\"_blank\">but slashed its FY26 sales guidance.</a></p><!--/$--><!--$--><p class=\"block core-block\">The company reported quarterly earnings of $1.01 per share, which beat the analyst consensus estimate of 90 cents, according to data from Benzinga Pro. Quarterly revenue came in at $815.75 million which beat the analyst consensus estimate of $798.82 million.</p><!--/$--><!--$--><div class=\"min-w-[300px] w-[300px] min-h-[250px] raptive-ad-placement mx-auto overflow-hidden min-w-[300px]\"></div><!--/$--><!--$--><p class=\"block core-block\">\"We believe Zscaler is the cybersecurity platform for the AI age — our in-line Zero Trust platform is uniquely architected to secure the unprecedented speed and scale of AI and agentic workflows,\" said Jay Chaudhry, CEO.</p><!--/$--><!--$--><p class=\"block core-block\">Zscaler raised its fiscal 2026 adjusted EPS from $3.99 to $4.02, versus the $3.81 estimate, and lowered its revenue outlook to a new range of $3.31 billion to $3.32 billion, versus the $3.3 billion estimate.</p><!--/$--><!--$--><p class=\"block core-block\">Zscaler shares fell 13.4% to $144.97 in pre-market trading.</p><!--/$--><!--$--><p class=\"block core-block\">These analysts made changes to their price targets on Zscaler following earnings announcement.</p><!--/$--><!--$--><ul class=\"wp-block-list\">\n<li>Needham analyst Mike Cikos maintained Zscaler with a Buy and lowered the price target from $310 to $180.</li>\n<li>Piper Sandler analyst Rob Owens maintained the stock with a Neutral and lowered the price target from $260 to $185.</li>\n<li>Citizens analyst Trevor Walsh maintained Zscaler with a Market Outperform and lowered the price target from $355 to $290.</li>\n</ul><!--/$--><!--$--><p class=\"block core-block\"><strong>Considering buying ZS stock? Here’s what analysts think:</strong> </p><!--/$--><!--$?--><template id=\"B:2\"></template><div></div><!--/$--><!--$--><p class=\"block core-block\">Photo via Shutterstock</p><!--/$--><!--$--><div class=\"bz-optimizely-campaign bz-optimizely-campaign-bottom-50927193\" data-nosnippet=\"true\"></div><!--/$--></div></div>",
            "image": "https://www.benzinga.com/files/images/story/2026/02/27/ZscalerFeb-14--2020-San-Jose-----Ca-----.jpeg",
            "link": "https://www.benzinga.com/analyst-stock-ratings/price-target/26/02/50927193/zscaler-analysts-slash-their-forecasts-after-q2-results",
            "pub_date": "2026-02-27 22:14:58",
            "source": "benzinga",
            "kind": 1,
            "language": "en"
        },
        {
            "id": "69a1a47624c37e0001bbf70c",
            "title": "Rhythm Pharmaceuticals Analysts Raise Their Forecasts After Upbeat Q4 Results",
            "description": "<div><div class=\"sc-gfrmXj kPLDLR\"><!--$--><p class=\"block core-block\"><strong>Rhythm Pharmaceuticals</strong> <a class=\"ticker-link\" data-exchange=\"NASDAQ\" data-ticker=\"RYTM\" href=\"https://www.benzinga.com/quote/RYTM\" rel=\"noopener\" target=\"_blank\">(NASDAQ:</a><a class=\"ticker\" href=\"https://www.benzinga.com/quote/RYTM\" target=\"_blank\">RYTM</a>)<!-- --> on Thursday posted upbeat results<a href=\"https://www.benzinga.com/quote/RYTM/earnings\" target=\"_blank\"> for the fourth quarter</a>.</p><!--/$--><!--$--><p class=\"block core-block\">The company posted a quarterly loss of 73 cents per share, versus market estimates of a loss of 81 cents per share. The company's sales came in at $57.253 million, versus expectations of $56.042 million.</p><!--/$--><!--$--><p class=\"block core-block\">“Rhythm delivered solid IMCIVREE global sales growth and made continued progress developing therapies to address hyperphagia and severe obesity for people with rare MC4R pathway diseases in 2025,” said David Meeker, M.D., Chairman, Chief Executive Officer and President of Rhythm. “We enter 2026 focused on long-term growth and well-capitalized to achieve important commercial and clinical milestones. We are prepared to bring IMCIVREE to patients with acquired HO in the United States, pending FDA approval.”</p><!--/$--><!--$--><p class=\"block core-block\">Rhythm Pharmaceuticals shares closed at $98.07 on Thursday.</p><!--/$--><!--$--><p class=\"block core-block\">These analysts made changes to their price targets on Rhythm Pharmaceuticals following earnings announcement.</p><!--/$--><!--$--><ul class=\"wp-block-list\">\n<li>Guggenheim analyst Seamus Fernandez maintained Rhythm Pharmaceuticals with a Buy and raised the price target from $140 to $143.</li>\n<li>Citizens analyst Jonathan Wolleben maintained the stock with a Market Outperform and raised the price target from $167 to $176.</li>\n</ul><!--/$--><!--$--><p class=\"block core-block\"><strong>Considering buying RYTM stock? Here’s what analysts think:</strong> </p><!--/$--><!--$?--><template id=\"B:2\"></template><div></div><!--/$--><!--$--><p class=\"block core-block\"><em>Photo: Shutterstock</em></p><!--/$--><!--$--><div class=\"bz-optimizely-campaign bz-optimizely-campaign-middle-50926785\" data-nosnippet=\"true\"></div><!--/$--></div></div>",
            "image": "https://www.benzinga.com/files/images/story/2026/02/27/Young-Couple-Is-Meeting-With-A-Financial.jpeg",
            "link": "https://www.benzinga.com/analyst-stock-ratings/price-target/26/02/50926785/rhythm-pharmaceuticals-analysts-raise-their-forecasts-after-upbeat-q4-results",
            "pub_date": "2026-02-27 22:04:41",
            "source": "benzinga",
            "kind": 1,
            "language": "en"
        }
    ]
}